Scarica l'app Stockscreener
586.30
0.83%
-4.895
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$591.20
Aprire:
$581.94
Volume 24 ore:
78,242
Relative Volume:
0.13
Capitalizzazione di mercato:
$25.15B
Reddito:
$3.17B
Utile/perdita netta:
$1.29B
Rapporto P/E:
21.64
EPS:
27.0947
Flusso di cassa netto:
$1.01B
1 W Prestazione:
+4.05%
1M Prestazione:
+20.75%
6M Prestazione:
+3.02%
1 anno Prestazione:
+41.16%
Intervallo 1D:
$581.88
$589.19
Intervallo di 1 settimana:
$562.86
$593.50
Portata 52W:
$409.07
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
586.30 | 25.15B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
20.11 | 64.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.16 | 46.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.03 | 44.11B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.28 | 31.94B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-01 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2026-09-24 | Iniziato | Goldman | Sell |
| 2026-05-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Underweight |
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
S&P 500 Futures Up in Premarket Trading; MSG Sports, United Therapeutics Lag - Barron's
United Therapeutics CEO sells $5.5M in stock By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 23 October - Investing.com Nigeria
After exercising options at $117.76, United Therapeutics (UTHR) CEO trusts sell 9,500 shares. - Stock Titan
United Therapeutics (NDQ:UNTR): The Only Company Attempting Xenotransplantation At Scale! - Stocks Down Under
U.S. transgender billionaire Martine Rothblatt sells $5.5 million in United Therapeutics stock - Billionaires.Africa
Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock - Investing.com
United Therapeutics Gets FDA Clearance to Start Phase 2 SUMMIT Trial of Treprostinil Soft Mist Inhaler in PH-COPD - BioBuzz
United Therapeutics to build a $9 million hangar at Rochester's airport - Post Bulletin
United Therapeutics CEO Rothblatt sells $5.3m in UTHR stock - Investing.com
Is United Therapeutics Corp (UTHR) Overvalued After 3.8% Rally? - GuruFocus
Generation Park lands new facility to scale xeno-organ production - InnovationMap
United Therapeutics authorizes $2 billion buyback program - Investing.com
United Therapeutics Authorizes Up to $2 Billion Share Repurchase - TradingView
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization - Yahoo Finance
United Therapeutics CEO Martine Rothblatt sells $5.26m in stock - Investing.com
CEO trusts sell 9,500 United Therapeutics (UTHR) shares after exercising stock options. - Stock Titan
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 - Yahoo Finance
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 19 October - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.16m in shares - Investing.com
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? - Yahoo Finance
United Therapeutics opens third xenograft production facility - Investing.com
A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan
United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth - The Business Journals
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility - Yahoo Finance
United Therapeutics chairperson & CEO sells $5.08m in shares By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October - Investing.com Nigeria
After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial o - GuruFocus
Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan
United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill
United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com
Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com
After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan
United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria
After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan
A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Liquidia shares surge 25% as settlement ends United Therapeutics litigation - Yahoo Finance
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Why Is Liquidia Stock Skyrocketing Wednesday?United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
A $10M payment is also due from United Therapeutics (UTHR) in its settlement with Liquidia. - Stock Titan
Liquidia shares surge to 5-month high premarket on United Therapeutics settlement - Yahoo Finance
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Shares Surge 42.48% After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 26 '26 |
Sale |
588.64 |
9,500 |
5,592,095 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 23 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 23 '26 |
Sale |
582.76 |
9,500 |
5,536,235 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 22 '26 |
Sale |
583.38 |
9,500 |
5,542,094 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 22 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 21 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 21 '26 |
Sale |
560.07 |
9,500 |
5,320,681 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 20 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 20 '26 |
Sale |
553.87 |
9,500 |
5,261,741 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 19 '26 |
Sale |
543.32 |
9,500 |
5,161,576 |
324,443 |
0.47%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):